This suppresses anti-tumor T cell responses and promotes tumor progression, suggesting that YBX1 facilitates immune evasion in ICC via regulation of RNA modifications and immune checkpoint signaling, providing a potential target for immunotherapy. This evidence concerns the gene YBX1 and intrahepatic cholangiocarcinoma.